louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06991933: Construction and Educational Impact of Plastination Models of the Limbic System, Basal Nuclei, Cerebellum, and Human Spinal Cord
Official title: Preparation and Construction of Volumetric Plastination Models of the Limbic System, Basal Nuclei, Cerebellum, and Human Spinal Cord and Evaluation of Their Educational Effects
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Education
Education, Medical
Education, Medical, Undergraduate
Keywords: Medical education
Neuroanatomy
plastination model
Lead sponsor: Isfahan University of Medical Sciences
Sponsor class: OTHER
First posted: 2025-05-28
Enrollment: 60
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: Purpose:

This educational trial aims to assess whether plastination models for neuroanatomy training (limbic system, basal ganglia, cerebellum, spinal cord)" improve medical students' understanding of central nervous system anatomy compared to traditional educational methods. It will also evaluate student satisfaction with this teaching tool.

Key Questions:

1. Do plastination models for neuroanatomy training (limbic system, basal ganglia, cerebellum, spinal cord) enhance test scores in neuroanatomy examinations?
2. How do students perceive the educational value of these models?

Study Design:

Researchers will compare two teaching methods:

* Intervention group: Learns using plastination models for neuroanatomy training (limbic system, basal ganglia, cerebellum, spinal cord)
* Control group: Learns using standard 2D atlases, power point and plastic models

Participants will:

1. Complete a pre-intervention anatomy knowledge test
2. Attend 4 weekly neuroanatomy sessions using their assigned method
3. Take a post-intervention exam and satisfaction survey
4. Participate in focus groups about their learning experience


Eligibility criteria: Inclusion Criteria:

* Medical students in their third semester of training
* Currently enrolled in neuroanatomy coursework at Isfahan University of Medical Sciences
* No prior formal training with plastinated models
* Willing to attend all study sessions for 7 weeks
* Able to complete assessments in persian

Exclusion Criteria:

* Prior experience with plastinated models
* Currently taking neuroanatomy remediation courses
* Planned absences during \>20% of study sessions

Primary outcomes:
measure: Change in neuroanatomy knowledge scores assessed by the "Neuroanatomy Knowledge Assessment Test
timeFrame: Baseline, Week 4 post-intervention
Secondary outcomes:
measure: Spatial understanding assessment
timeFrame: Post-intervention only
measure: Student satisfaction assessed by the 10-item Student Satisfaction Survey (SSS)
timeFrame: Immediately after the intervention (Day 1)
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01804933: Influence of Profound Muscle Relaxation on Muscle Trauma and Postoperative Pulmonary Function
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Profound Muscle Relaxation
Muscle Trauma
Postoperative Analgesic Demand
Postoperative Pulmonary Function
Keywords: profound muscle relaxation
muscle trauma
postoperative analgesic demand
postoperative pulmonary function
Lead sponsor: First Affiliated Hospital, Sun Yat-Sen University
Sponsor class: OTHER
First posted: 2013-03-05
Enrollment: 72
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Although deep anesthesia can produce skeleton muscle relaxation,unnecessary deep anesthesia often had adverse cardiac effects and was related to 2-year mortality in cancer patients.The use of muscle relaxants allowed the depth of anesthesia to be optimized.However, for many anesthesiologists,in fear of residual postoperative neuromuscular blockade,intraoprative administration of muscle relaxants had to be minimized in spite of poor surgical conditions.

This study, however, is designed to test the hypothesis that profound neuromusclular blockade reduces muscle trauma caused by self-retaining retractor and thus cut down postoperative analgesic requirement.On the other hand,profound muscle relaxation can decrease postoperative diaphragmatic dysfunction and abdominal muscle trauma, which can improve postoperative pulmonary function.


Eligibility criteria: Inclusion Criteria:

* ASA 1\~2,scheduled to undergo upper abdominal surgery by midline incision

Exclusion Criteria:

* neuromuscular disorder
* history of malignant hyperthemia
* allergy to medications used during general anesthesia

Primary outcomes:
measure: degree of muscle trauma
timeFrame: 72h postoperatively
Secondary outcomes:
measure: postoperative analgesic requirement
timeFrame: 7days postoperatively
Other outcomes:
measure: postoperaive pulmonary function
timeFrame: 3days postoperatively
Locations:
city: Guangzhou
country: China
facility: The First Affiliated Hospital of Sun Yat-sen University
state: Guangdong
Study officials:
affiliation: First Affiliated Hospital, Sun Yat-Sen University
name: Ying Xiao, MD, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT00979433: Bubble Continuous Positive Airway Pressure (CPAP) With Conventional CPAP for Extubation in Preterm Infants
Official title: Bubble CPAP vs. Conventional CPAP Following Extubation in Preterm Very Low Birth Weight (VLBW) Infants: A Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Extubation Failure
Keywords: Extubation failure
Continuous positive airway pressure
Bubble CPAP
Lead sponsor: All India Institute of Medical Sciences
Sponsor class: OTHER
First posted: 2009-09-18
Enrollment: 32
Sex: ALL
Maximum age (years): 7
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The objective of this study is to evaluate whether CPAP delivered by bubble CPAP resulted in a greater proportion of infants being successfully extubated when compared with management with ventilator derived CPAP.

Detailed description: There have been no published randomized trials comparing extubation failure rates of Bubble CPAP with conventional ventilator derived CPAP. Infants of gestation \<32 weeks and of birth weight less than 1500 grams considered by the treating team to be ready for the initial extubation within first week of life were screened for enrolment. All eligible neonates were randomly allocated to bubble CPAP or conventional CPAP.The purpose of this study is to compare whether infants on Bubble CPAP had more chances of successful extubation as compared to infants put on Conventional CPAP.

Eligibility criteria: Inclusion Criteria:

* Gestation less than 32 weeks
* Birth weight less than 1500 g
* Age less than seven days
* First extubation attempt.

Exclusion Criteria:

* A neonate having any of the following will be excluded from the study-
* Severe birth asphyxia defined as need for chest compression for more than 30 seconds
* Suspected congenital neuromuscular disorder
* Major congenital malformation
* Grade 3/4 interventricular haemorrhage
* Hydrops.

Primary outcomes:
measure: Extubation failure - defined as need for reintubation and mechanical ventilation for any reason within 72 hours of initial extubation
timeFrame: Till 72 hours after extubation
Secondary outcomes:
measure: Time to extubation failure in hours.
timeFrame: till extubation failure within first 72 hours after extubation
Other outcomes:
Locations:
city: New Delhi
country: India
facility: All India Institute of Medical Sciences
state: Delhi
Study officials:
affiliation: Department of Pediatrics, All India Institute of Medical Sciences, New Delhi
name: Vinod K Paul, MD PhD
role: STUDY_CHAIR
affiliation: Department of Pediatrics, All India Institute of Medical Sciences, New Delhi
name: Sucheta Yadav, MBBS
role: PRINCIPAL_INVESTIGATOR
affiliation: Department of Pediatrics, All India Institute of Medical Sciences, New Delhi
name: Mari J Sankar, MD, DM
role: STUDY_CHAIR
affiliation: Department of Pediatrics, All India Institute of Medical Sciences, New Delhi
name: Ramesh Agarwal, MD, DM
role: STUDY_CHAIR
References:
Clinical trial NCT03133533: Laparoscopic Versus Robot-assisted Inguinal Hernia Repair: A Single Institution Randomized Controlled Trial
Official title: Laparoscopic Versus Robot-assisted Inguinal Hernia Repair: The Immediate, Intermediate, and Long Term Outcome Differences. A Single Institution Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Hernia, Inguinal
Keywords: robot-assisted
Lead sponsor: University of Florida
Sponsor class: OTHER
First posted: 2017-04-28
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Participants will be randomized to receive either laparoscopic or robot-assisted repair of inguinal hernia.
Primary purpose: TREATMENT

Brief summary: Randomized trial to compare outcomes of laparoscopic and robot assisted inguinal hernia repair.

Detailed description: Inguinal hernia repair is a very common surgical operation. Both laparoscopic and robot-assisted operations are considered acceptable. However, there is no clear indication for a particular approach. No prospective trial has been conducted so far to establish superiority of one approach over the other. The Investigator believes each approach has unique characteristics and may offer advantages over the other in the right population group. The Investigator will randomly assign patients in two arms according to the surgical approach, whether laparoscopic or robot-assisted. The Investigator will collect preoperative characteristics, intraoperative variables, and postoperative outcomes. The Investigator will compare all variables to establish differences between the two groups.

Eligibility criteria: Inclusion Criteria:

* surgeon determined need for inguinal hernia repair

Exclusion Criteria:

* \< 18 years of age
* \> 99 years of age
* medical indication for open repair

Primary outcomes:
measure: Operative time
timeFrame: Immediate perioperative time
Secondary outcomes:
measure: Postoperative pain score
timeFrame: Until 5 year postoperative
Other outcomes:
measure: Complications
timeFrame: From immediately post-operative until year five following surgical inguinal hernia repair.
Locations:
city: Gainesville
country: United States
facility: University of Florida
state: Florida
Study officials:
affiliation: University of Florida
name: Michael Latzko, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00541333: Weekly Vaccination With Copaxone as a Potential Therapy for Dry Age-related Macular Degeneration
Official title: Weekly Vaccination With Copaxone as a Potential Therapy for Dry Age-related Macular Degeneration
Study type: INTERVENTIONAL
Overall status: SUSPENDED
Phase: PHASE1
Conditions: Dry Age Related Macular Degeneration
Keywords: Dry Age Related Macular Degeneration
Dry AMD
Lead sponsor: The New York Eye & Ear Infirmary
Sponsor class: OTHER
First posted: 2007-10-10
Enrollment: 15
Sex: ALL
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of the project is to investigate in eyes with dry AMD, the efficacy and safety as preventive therapy of the immunomodulatory substance named copaxone which had been proven as safe and effective agent for a neurodegenerative disease, in arresting the progression as well as the conversion of dry AMD to wet AMD. The hypothesis that the immunomodulatory agent copaxone proven for a neurodegenerative disease may work in the eye is revolutionary and may open a new avenue of preventive treatment for the disease which is the major cause of legal blindness in the industrial world


Eligibility criteria: Inclusion Criteria:

1. Dry AMD in one or both eyes
2. Age 50 or above of either gender
3. Signed informed consent.

Exclusion Criteria:

1. Known sensitivity to Mannitol or Copaxone.
2. Skin disease or active infection of skin.
3. Active fever or active treatment for infection.
4. History of other uncontrolled systemic active disease.
5. Premenopausal females not using reliable birth control.
6. Sensitivity to fluorescein or iodine.
7. Inability to comply with study procedures.

Primary outcomes:
measure: Total drusen area reduction
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: New York
country: United States
facility: New York Eye and Ear Infirmary
state: New York
Study officials:
affiliation: New York Eye and Ear Infirmary
name: Richard B Rosen, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03071133: Real-world Incidence Proportion of Hepatic Toxicity and All Adverse Drug Reactions (ADRs) in Japanese Patients Receiving Daclatasvir (DCV) Trio Therapy
Official title: Asunaprevir/Daclatasvir/Beclabuvir Fixed-Dose Combination Safety Surveillance in Japanese Patients With Chronic Hepatitis C (HCV) or Japanese Patients With Compensated Cirrhosis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hepatitis C
Lead sponsor: Bristol-Myers Squibb
Sponsor class: INDUSTRY
First posted: 2017-03-06
Enrollment: 344
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients in Japan who are initiating treatment with DCV Trio therapy

Brief summary: An observational, postmarketing commitment following the marketing authorization for DCV Trio therapy in Japan


Eligibility criteria: Inclusion Criteria:

* Patients who are initiating the treatment with DCV Trio therapy under the approved indications, dosage, and administration

Exclusion Criteria:

* Patients who use the DCV Trio off label

Primary outcomes:
measure: Incidence of Aspartate Aminotransferase (AST) elevation
timeFrame: Up to 36 weeks
measure: Incidence of Alanine Aminotransferase (ALT) elevation
timeFrame: Up to 36 weeks
measure: Incidence of Total Bilirubin (tBili) elevation
timeFrame: Up to 36 weeks
Secondary outcomes:
measure: Incidence of adverse drug reactions (ADRs) in HCV patients treated with DCV Trio therapy in Japan
timeFrame: Up to 36 weeks
measure: Proportion of patients with undetectable HCV RNA at 12 weeks post-treatment (SVR12)
timeFrame: Up to 24 weeks
measure: Proportion of patients with undetectable HCV RNA at 24 weeks post-treatment (SVR24)
timeFrame: Up to 36 weeks
measure: Percentage of patients to experience virologic breakthrough
timeFrame: Up to 36 weeks
Other outcomes:
Locations:
city: Tokyo
country: Japan
facility: Local Institution
Study officials:
affiliation: Bristol-Myers Squibb
name: Bristol-Myers Squibb
role: STUDY_DIRECTOR
References:
Clinical trial NCT06374433: Investigating the Plasticity of Human Predictive Coding Through Neuromodulation
Official title: Investigating the Plasticity of Human Predictive Coding Through Neuromodulation: an Interventional, Monocentric, Randomized, Single-blinded Study on Healthy Adult Volunteers
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Human Brain and Cognition
Lead sponsor: Università Vita-Salute San Raffaele
Sponsor class: OTHER
Collaborators: name: Alessia Santoni
name: Sara Stottmeier
name: Klara Hemmerich
name: Giuseppe Di Dona
name: Luigi Ferini-Strambi
First posted: 2024-04-18
Enrollment: 210
Sex: ALL
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: The hypothesis of the study is to investigate how different trm (tES) methods (transcranial Alternating Current Stimulation, tACS, and transcranial Random Noise Stimulation, tRNS) applied at different stimulation frequencies and networks can modulate the predictive mechanisms in human perception and cognition. This is an interventional, monocentric, cross-sectional randomized, single-blinded study on healthy adult volunteers, recruited through online advertisements, flyers and oral transmission. Volunteers will be recruited from the general population of young adults.


Eligibility criteria: Inclusion Criteria:

* Participant is willing and able to give informed consent for participation in the study.
* Aged 18-35 years.
* Normal or corrected to normal vision, as per anamnestic investigation.

Exclusion Criteria:

* Participants with a diagnosis of epilepsy (as per anamnestic investigation).
* Participants with major neurological disorders (as per anamnestic investigation).
* Participants that are currently under psychopharmacological treatment with tricyclic antidepressants (as per anamnestic investigation).
* Participants with metal implants in the brain, pacemakers, brain stimulators, cochlear implants (as per anamnestic investigation).

Primary outcomes:
measure: Behavioral measures
timeFrame: During the procedure
Secondary outcomes:
Other outcomes:
Locations:
city: Milan
country: Italy
facility: Università Vita-Salute San Raffaele
Study officials:
References:
Clinical trial NCT01850433: Internet Cognitive Behavior Therapy (CBT) for Body Dysmorphic Disorder (BDD)
Official title: Internet-based Cognitive Behavior Therapy for Body Dysmorphic Disorder: A Pilot Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Body Dysmorhpic Disorder
Keywords: BDD
CBT
Lead sponsor: Karolinska Institutet
Sponsor class: OTHER
First posted: 2013-05-09
Enrollment: 23
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The primary aim is to develop, and test the feasibility, of a novel and protocol-based cognitive behaviour therapy (CBT) treatment for body dysmorphic disorder (BDD) administered via the Internet.


Eligibility criteria: Inclusion Criteria:

* outpatients
* male or female

  -≥ 18 years
* currently living in Stockholm county
* primary diagnosis of BDD according to the DSM-IV-TR
* signed informed consent
* regular access to a computer with Internet access and skills to use the web.

Exclusion Criteria:

* psychotropic medication changes within two months prior to the treatment
* completed CBT for BDD within the last 12 months
* BDD-YBOCS \< 12 at psychiatrist visit
* other primary axis I diagnosis
* current substance dependence
* lifetime bipolar disorder or psychosis
* suicidal ideation
* Axis II diagnosis that could jeopardize treatment participation
* other current psychological treatment that could affect BDD symptoms

Primary outcomes:
measure: Body dysmorphic disorder symptoms
timeFrame: Measured after 12 weeks of treatment, and after 3 months after treatment
Secondary outcomes:
measure: Functioning and life satisfaction
timeFrame: After 12 weeks of treatment, and 3 months after treatment
measure: Depressive symptoms
timeFrame: After 12 weeks of treatment, and 3 months after treatment
Other outcomes:
Locations:
city: Stockholm
country: Sweden
facility: M46 Huddinge sjukhus, Internetpsykiatrienheten/mottagningen för tvångssyndrom
Study officials:
affiliation: Karolinska Institutet
name: Christian Rück, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Enander J, Ivanov VZ, Andersson E, Mataix-Cols D, Ljotsson B, Ruck C. Therapist-guided, Internet-based cognitive-behavioural therapy for body dysmorphic disorder (BDD-NET): a feasibility study. BMJ Open. 2014 Sep 25;4(9):e005923. doi: 10.1136/bmjopen-2014-005923.
Clinical trial NCT05688033: Dosimetric Limitation of Pelvic Bone and Peritoneal Space in Rectal Cancer Patients During Chemoradiotherapy
Official title: Dosimetric Limitation of Pelvic Bone and Peritoneal Space in Rectal Cancer Patients During During Neoadjuvant Chemoradiation With Capecitabine and Irinotecan
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Rectal Cancer
Lead sponsor: Fudan University
Sponsor class: OTHER
First posted: 2023-01-18
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This project first retrospectively analyzes the intestinal dose indicators related to the concurrent radiotherapy and chemotherapy of rectal cancer and gastrointestinal toxicity, and the pelvic dose indicators related to hematological toxicity, and then prospectively conducts radiotherapy based on the dose indicators most closely related to toxicity. The dose is limited when the plan is made to reduce the gastrointestinal and hematological toxicity of rectal cancer with concurrent radiotherapy and chemotherapy.


Eligibility criteria: Inclusion Criteria:

1. Patients with rectal adenocarcinoma
2. Clinical staged T3/4 or any node-positive disease
3. Age of 18-75 years
4. Karnofsky Performance Status \> 80
5. Adequate bone marrow reserve, renal and hepatic functions
6. Without previous antitumoural chemotherapy
7. No evidence of metastatic disease
8. Written informed consent before randomization
9. UGT1A1's genotype of 6/6 or 6/7

Exclusion Criteria:

1. Clinical staged I or IV
2. Age of \<18 or \>75 years
3. Karnofsky Performance Status \< 80
4. Previous pelvis radiotherapy
5. Previous antitumoural chemotherapy
6. Clinically significant internal disease
7. Refuse to write informed consent before randomization
8. UGT1A1's genotype of 7/7

Primary outcomes:
measure: Number of Participants Experiencing Adverse Events
timeFrame: up to 3 years
Secondary outcomes:
measure: Number of Participants in Who Experienced Tumor Down-staging
timeFrame: up to 3 years
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Fudan University Shanghai Cancer Center
state: Shanghai
Study officials:
affiliation: Fudan University
name: Zhen Zhang
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01216033: Exploratory Study of Breast Cancer With ABY025
Official title: An Exploratory Study to Evaluate the Distribution of [111In]ABY-025 Uptake for SPECT Imaging in Subjects With Metastatic Breast Cancer
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Breast Cancer
Keywords: Breast cancer
Diagnostics
HER2
Imaging
Metastases
SPECT
Imaging of metastases
Lead sponsor: Biomedical Radiation Sciences
Sponsor class: OTHER
Collaborators: name: Swedish Cancer Society
First posted: 2010-10-07
Enrollment: 7
Sex: FEMALE
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The aim is to study if breast cancer metastases accumulate the newly developed HER2 binding molecule 111-In-ABY025 and if that shows whether the metastases express HER2.


Eligibility criteria: Inclusion Criteria:

* female age \>20 years
* one or more known metastases localizations

Exclusion Criteria:

* other critical disease than breast cancer
* age ≤ 20 years

Primary outcomes:
measure: Imaging of metastases
timeFrame: One year
Secondary outcomes:
measure: Can the new molecule be used for imaging in extended studies
timeFrame: October 2010 - June 2011
Other outcomes:
Locations:
city: Uppsala
country: Sweden
facility: Akademiska Hospital
state: Uppland
Study officials:
References:
citation: Carlsson J, Nordgren H, Sjostrom J, Wester K, Villman K, Bengtsson NO, Ostenstad B, Lundqvist H, Blomqvist C. HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review. Br J Cancer. 2004 Jun 14;90(12):2344-8. doi: 10.1038/sj.bjc.6601881.